Humacyte is trading 5.29% up now at $0.58 after the August 13 selloff, with no confirmed fresh catalyst.
- Shares fell 17.29% to $0.55 after the August 12 earnings report; second-quarter revenue was $410,000 versus $1.11 million expected, while EPS missed by $0.07.
- Major indexes are up roughly 0.05%-0.08%; the rebound appears technically driven or speculative, and no August 14 announcement clearly explains it.